157 related articles for article (PubMed ID: 7968278)
1. Alterations in intrahepatic expression of duck hepatitis B viral markers with ganciclovir chemotherapy.
Luscombe C; Pedersen J; Bowden S; Locarnini S
Liver; 1994 Aug; 14(4):182-92. PubMed ID: 7968278
[TBL] [Abstract][Full Text] [Related]
2. Effect of nucleoside analogue therapy on duck hepatitis B viral replication in hepatocytes and bile duct epithelial cells in vivo.
Nicoll A; Locarnini S; Chou ST; Smallwood R; Angus P
J Gastroenterol Hepatol; 2000 Mar; 15(3):304-10. PubMed ID: 10764033
[TBL] [Abstract][Full Text] [Related]
3. Long-term ganciclovir chemotherapy for congenital duck hepatitis B virus infection in vivo: effect on intrahepatic-viral DNA, RNA, and protein expression.
Luscombe C; Pedersen J; Uren E; Locarnini S
Hepatology; 1996 Oct; 24(4):766-73. PubMed ID: 8855174
[TBL] [Abstract][Full Text] [Related]
4. Reversion of duck hepatitis B virus DNA replication in vivo following cessation of treatment with the nucleoside analogue ganciclovir.
Dean J; Bowden S; Locarnini S
Antiviral Res; 1995 May; 27(1-2):171-8. PubMed ID: 7486954
[TBL] [Abstract][Full Text] [Related]
5. Decrease of wild-type and precore mutant duck hepatitis B virus replication during lamivudine treatment in white Pekin ducks infected with the viruses.
Tomita T; Yokosuka O; Tagawa M; Saisho H; Tamura S; Fukuda I; Omata M
J Hepatol; 2000 May; 32(5):850-8. PubMed ID: 10845674
[TBL] [Abstract][Full Text] [Related]
6. Covalently closed circular DNA is the predominant form of duck hepatitis B virus DNA that persists following transient infection.
Le Mire MF; Miller DS; Foster WK; Burrell CJ; Jilbert AR
J Virol; 2005 Oct; 79(19):12242-52. PubMed ID: 16160150
[TBL] [Abstract][Full Text] [Related]
7. Oral famciclovir against duck hepatitis B virus replication in hepatic and nonhepatic tissues of ducklings infected in ovo.
Tsiquaye KN; Slomka MJ; Maung M
J Med Virol; 1994 Mar; 42(3):306-10. PubMed ID: 8006644
[TBL] [Abstract][Full Text] [Related]
8. Antiviral effects of PNA in duck hepatitis B virus infection model.
Chen ZY; Cheng AC; Wang MS; Xu DW; Zeng W; Li Z
Acta Pharmacol Sin; 2007 Oct; 28(10):1652-8. PubMed ID: 17883953
[TBL] [Abstract][Full Text] [Related]
9. Evidence that hepatocyte turnover is required for rapid clearance of duck hepatitis B virus during antiviral therapy of chronically infected ducks.
Fourel I; Cullen JM; Saputelli J; Aldrich CE; Schaffer P; Averett DR; Pugh J; Mason WS
J Virol; 1994 Dec; 68(12):8321-30. PubMed ID: 7966625
[TBL] [Abstract][Full Text] [Related]
10. [Inhibitory effect of trisodium phosphonoformate (PFA) on duck hepatitis B virus (DHBV) DNA in vivo].
Chen X; Chen H
Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi; 1997 Sep; 11(3):277-81. PubMed ID: 15617348
[TBL] [Abstract][Full Text] [Related]
11. Duck hepatitis B virus replication in primary bile duct epithelial cells.
Lee JY; Culvenor JG; Angus P; Smallwood R; Nicoll A; Locarnini S
J Virol; 2001 Aug; 75(16):7651-61. PubMed ID: 11462037
[TBL] [Abstract][Full Text] [Related]
12. The guanine nucleoside analog penciclovir is active against chronic duck hepatitis B virus infection in vivo.
Lin E; Luscombe C; Wang YY; Shaw T; Locarnini S
Antimicrob Agents Chemother; 1996 Feb; 40(2):413-18. PubMed ID: 8834889
[TBL] [Abstract][Full Text] [Related]
13. The persistence in the liver of residual duck hepatitis B virus covalently closed circular DNA is not dependent upon new viral DNA synthesis.
Reaiche GY; Le Mire MF; Mason WS; Jilbert AR
Virology; 2010 Oct; 406(2):286-92. PubMed ID: 20705309
[TBL] [Abstract][Full Text] [Related]
14. Vaccination of ducks with a whole-cell vaccine expressing duck hepatitis B virus core antigen elicits antiviral immune responses that enable rapid resolution of de novo infection.
Miller DS; Halpern M; Kotlarski I; Jilbert AR
Virology; 2006 May; 348(2):297-308. PubMed ID: 16469347
[TBL] [Abstract][Full Text] [Related]
15. Antiviral therapy with entecavir combined with post-exposure "prime-boost" vaccination eliminates duck hepatitis B virus-infected hepatocytes and prevents the development of persistent infection.
Miller DS; Boyle D; Feng F; Reaiche GY; Kotlarski I; Colonno R; Jilbert AR
Virology; 2008 Apr; 373(2):329-41. PubMed ID: 18206204
[TBL] [Abstract][Full Text] [Related]
16. Effects of liver growth factors on hepadnavirus replication in chronically infected duck hepatocytes.
Schorr O; Borel C; Trepo C; Zoulim F; Hantz O
J Hepatol; 2006 May; 44(5):842-7. PubMed ID: 16458387
[TBL] [Abstract][Full Text] [Related]
17. Enhanced duck hepatitis B virus gene expression following aflatoxin B1 exposure.
Barraud L; Guerret S; Chevallier M; Borel C; Jamard C; Trepo C; Wild CP; Cova L
Hepatology; 1999 Apr; 29(4):1317-23. PubMed ID: 10094981
[TBL] [Abstract][Full Text] [Related]
18. Characterization of age- and dose-related outcomes of duck hepatitis B virus infection.
Jilbert AR; Botten JA; Miller DS; Bertram EM; Hall PM; Kotlarski J; Burrell CJ
Virology; 1998 May; 244(2):273-82. PubMed ID: 9601498
[TBL] [Abstract][Full Text] [Related]
19. DNA vaccination in combination or not with lamivudine treatment breaks humoral immune tolerance and enhances cccDNA clearance in the duck model of chronic hepatitis B virus infection.
Thermet A; Buronfosse T; Werle-Lapostolle B; Chevallier M; Pradat P; Trepo C; Zoulim F; Cova L
J Gen Virol; 2008 May; 89(Pt 5):1192-1201. PubMed ID: 18420797
[TBL] [Abstract][Full Text] [Related]
20. Long-term therapy with the guanine nucleoside analog penciclovir controls chronic duck hepatitis B virus infection in vivo.
Lin E; Luscombe C; Colledge D; Wang YY; Locarnini S
Antimicrob Agents Chemother; 1998 Aug; 42(8):2132-7. PubMed ID: 9687423
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
